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It is a great honor to give the annual Sir John Crawford Lecture.  
 
I do not know as much about agriculture as many of you do, but I 
certainly appreciate its central place in biology and in the genomic 
revolution. I will focus instead on some of the genomes I have 
characterized with my colleagues at The Institute for Genomic 
Research and at Celera. And I will talk about why characterizing 
genomes is important. I'll even try and tell you a little about your 
own genetic code and how that might be relevant to your health.  
 
The history of genomics is remarkably short and yet we have 
accomplished a great deal. In 1992, Dr. Claire Fraser and I left the 
National Institutes of Health (NIH) to form the first not-for-profit 
research institute devoted to genomics, The Institute for Genomic 
Research (TIGR). We had funding of $85 million for ten years from 
Wally Steinberg, a strong supporter and entrepreneur. In exchange, a 
parallel for-profit entity, Human Genome Sciences, would get access 
to the research to develop the discoveries made by TIGR into new 
therapeutics. 
 
We set up the first large-scale DNA sequencing facility using what 
was thought of at that time as untried technology, automated DNA 
sequencers made by Applied Biosystems. 
 
In 1994 we made a transition. TIGR began using the expressed 
sequence tags (EST) method I developed at NIH, a method for 
rapidly discovering genes without sequencing the entire genomes. 
We developed new mathematical algorithms to deal first with tens of 
thousands of sequences and then hundreds of thousands and now 
millions of sequences. And we decided we could go back and 
rethink how to approach genomics. Our colleague, Hamilton Smith, 
who shared the Nobel Prize in 1978 for the discovery of restriction 
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endonucleases, suggested we use a microbial pathogen. He 
suggested his favorite, Haemophilus influenzae, the major cause of ear 
infections in children and a major cause of meningitis. Virtually 
nothing was known about this organism, even though Dr. Smith 
isolated the first restriction enzymes from Haemophilus influenzae. 
 
We decided we could use our new mathematical approach and 
sequence this genome relatively rapidly, given that the benchmark at 
that time was the E. coli  genome, which is slightly larger than 
Haemophilus. The E. coli  project was in its ninth year of federal 
funding and, in fact, it took a total of 12 years for the public effort to 
sequence the E. coli  genome. 
 
We thought we could do better. We wrote a grant and submitted it 
to NIH saying we could sequence the Haemophilus genome in one 
year at a tiny fraction of the cost. We named the new strategy for 
decoding genomes “whole genome shotgun sequencing.” We 
decided the chances of this grant getting funded were relatively low, 
so we went ahead and used some of the TIGR endowment to 
sequence this genome. 
 
In 1995, when we had it 90 percent completed, NIH said that what 
we were proposing was impossible and they would not fund it. A 
short while later, the Haemophilus genome sequence was published 
in Science. It was the first sequenced genome of any free-living 
organism. 
 
This has changed the paradigm of what can be done, and things 
have accelerated quite dramatically since then. A partial list of 
genomes that have now been completely sequenced by largely the 
same scientific team both at TIGR and at Celera includes a large 
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number of key pathogens, some very interesting environmental 
organisms that changed our view of the very nature of life itself. The 
first of these, Methanococcus jannaschii, came from a hypothermal 
vent a mile and a half deep in the Pacific Ocean. The temperature in 
the center of the vent is about 400 degrees Centigrade and the 
surrounding water is 2 degrees Centigrade. This organism makes 
everything it needs for life just from carbon dioxide, using hydrogen 
as an energy source. It is a true autotroph. Humans cannot do that. 
We need more than just CO2 and hydrogen. At our body temper-
atures, this organism is frozen solid. At about 60 degrees Centigrade 
it comes to life. Its optimum temperature for growth is 85 degrees 
Centigrade. It's totally happy in boiling water. 
 
Another sequence of an organism published by TIGR is the 
Deinococcus radiodurans genome, one of my favorites. It is literally 
like something from outer space. This organism can take three 
million rads of radiation and not be killed. Its chromosomes get 
broken apart with one or two hundred double-stranded breaks, but 
over a period of 12 to 14 hours it stitches its chromosomes back 
together and starts replicating again. Humans cannot do that either. 
Not even in Washington! 
 
Francis Crick, one of the co-discoverers of the structure of DNA, had 
a theory, developed by others as well, called panspermia, that states 
life did not originate on Earth; it came from another part of the 
universe, and once it arrived on this planet, it then evolved further. It 
was not believed that life could survive in the environ ment of outer 
space. But Deinococcus is actually an excellent candidate for a 
panspermia organism. It can be completely desiccated. It has been 
found, in that state, on granite surfaces in Antarctica, where perhaps 
it's been for a very long time. It can absorb huge doses of ionizing 
radiation. Drop it in water and it starts to reassemble the badly 
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damaged chromosome and starts replicating again. So it could have 
very easily arrived on a meteor some time in our past, or in some 
organism related to us. 
 
As we find these kinds of creatures of radiation resistance and tem-
perature resistance, it becomes clear that they are not at all unusual, 
they're not even rare. So it changes our view of the focus of life. 
These organisms also have some tremendous tools for us. 
 
The cholera genome was recently published by TIGR in Nature . 
Many scientists thought it was pointless to sequence the cholera 
genome because sixteen RNA studies showed it was exactly like the 
E. coli  genome and there would be nothing to learn from it.  Every 
genome that we have examined has held tremendous surprises. This 
was no different. Vibrio cholerae did not have one chromosome, as the 
field had assumed for years, it had two. And one of them did, in fact, 
resemble E. coli. The other didn't resemble E. coli at all, and that one 
is probably responsible for a lot of the actions and biology of cholera. 
 
So whole genome shotgun sequencing has no preconceived notions. 
In every case some grand illusions have been shattered by it. In some 
of the first genomes of pathogens, one of the shattered illusions is 
that evolution does not happen just by random errors. We found 
built-in mechanisms for active change of the genetic code in essen-
tially every human pathogen and most organisms. It is possible that 
everyone has Haemophilus influenzae  in the airway, because in front of 
most of the genes that code for cell surface antigens are tetrameric 
repeats, and in every 10,000 or so replications of this bacteria, the 
DNA polymerase slips on these repeats and puts stop codons in the 
gene downstream, effectively knocking out the gene. This constantly 
changes the cell surface molecules to avoid the immune system. So it 
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is a real-time Darwinian evolution, not from random changes, but 
from pre-programmed evolutionary changes built forever into the 
genetic code. And that is why it was such a disaster when, in the late 
1970s, the U.S. Surgeon General announced that we had won the war 
against microbes. 
 
We have seen these mechanisms in essentially every pathogen that 
we have looked at. They have tremendous consequences. One com-
pany tried to develop new vaccines against Haemophilus, but ignored 
these mechanisms—taking every cell surface antigen and making an 
antibody against it, and they got great vaccines against that one 
strain of Haemophilus. But as soon as they went into the clinic, the 
vaccines didn't work anymore. 
 
We could have predicted that. Chiron Corporation decided to listen 
to us. They funded a project at TIGR to sequence another major 
cause of meningitis, the Neiseria meningitidis genome. At the same 
time they wanted to use TIGR's ability to interpret the genetic code 
to tell them what candidates they might use for vaccine 
development. 
 
Approximately a year later, the paper was published in Science , 
along with another study simultaneously describing two new 
vaccine candidates that are now about ready to go into clinical trials 
with Chiron, because they seemed to work against a very broad 
array of strains of Neiseria meningitidis, for which there is currently 
no vaccine. So vaccine development is one of the key areas. We can 
go directly from finding the genetic code, use the information we 
learn, and potentially have major preventative treatments for major 
diseases. This is a theme you'll hear over and over again. 
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When we had the first genome and had the complete set of genes 
laid out in front of us, we decided it was too much for the human 
mind to interpret and comprehend even 1,800 genes – at least for my 
human mind and those of my colleagues at TIGR. And we went out 
looking for a simpler organism to see if there was something smaller 
and easier to comprehend. 
 
Clyde Hutchinson, of the University of North Carolina, had been 
characterizing Mycoplasma genitalium, and argued that it probably 
had the smallest genome of any free-living organism. Dr. Fraser led a 
team at TIGR to sequence this genome in three months. It was the 
second genome done in history and it was published in Science. It 
had only around 475 genes, and so we just asked the simple 
question: Well, if Haemophilus needs 1,800 genes and this one only 
needs 475, is 475 the minimum, or could this get by with less? Could 
we come up with a molecular definition for life based on the gene 
content of a species? 
 
A while later, another Mycoplasma species was sequenced, 
Mycoplasma pneumoniae, and it demonstrates a key feature of 
evolution that most people do not appreciate; that it is not only the 
addition of complexity and genetic material that leads to evolution, 
particularly with human pathogens. A lot of human pathogens 
evolve as pathogens by throwing out genetic material. So these two 
Mycoplasmae, around 500 and 700 genes, probably evolved from a 
5,000 gene B.subtilis-type organism by throwing out things they 
didn't need because they could get those pathways and nutrients 
from us as a host. 
 
All the genes in Mycoplasma genitalium were contained in the 
pneumoniae  genome, but pneumoniae had 200 extra genes. So if we 
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were studying pneumoniae, we could say we could throw out 200 
genes and get down to Mycoplasma genitalium. 
 
To make a very long story short, we developed a method originated 
by Clyde Hutchinson called “whole genome transposon 
mutagenesis.” Basically, we use electrical power to get small genetic 
elements into the cell, and then they randomly insert into the genetic 
code.  
 
If they insert in the middle of a gene, it disrupts that gene the same 
way as the mutants from the slip strand mechanisms do. The ones 
we deemed essential were ones that if knocked out, the cell dies. It's 
a pretty simple definition. 
 
After analyzing all these data, we got down to around 300 genes that 
we calculated to be essential for life. Of the 300 genes, 103 genes are 
completely unknown to science. We have not a clue what they do 
except that if you remove them from the genome, the cell dies. 
 
It's very humbling when we are now trying to analyze our own 
genetic code, to try to understand how 30,000 or 40,000 genes in 100 
trillion different combinations lead to our own biology. The other 
notion that we had of trying to define life at a molecular level, to find 
the secret code for life, fell apart pretty rapidly because we 
discovered what most social biologists knew for a long time; that the 
environment is important. It's nice for a molecular biologist to 
discover that. In fact, it is even nicer to prove it. We proved it with 
this study. We could not define a set of genes outside of defining the 
environment. In a very simple example, a cell will grow on both 
glucose and fructose. And there is a gene for the transporter for each 
one of these. 
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If we knock out the glucose transporter, as long as there is fructose in 
the environment, the cell is totally happy and continues to live and 
replicate. If we knock out both transporters, the cell dies. But if you 
knock out the glucose transporter and there is only glucose in the 
environment, the cell also dies. 
 
So you cannot define the molecular basis of any living entity without 
defining the corresponding environment. That is a major revelation 
for a molecular biologist. 
 
We moved on to more complex species. TIGR wanted to characterize 
a number of species that affected a large number of people. Steve 
Hoffman, who is now at Celera, received the Legion of Merit Award 
from the Secretary of the Navy for initiating the malaria genome 
program. Malaria is caused by a mosquito taking a blood meal and 
at the same time injecting the malaria parasite. 
 
The malaria genome was thought to be unsequenceable because of 
the high content of the nucleotides Adenine and Thymine. We found 
that it was readily sequenceable, but there was no map of the 
genome, and no way to characterize it. So we used some novel 
techniques. 
 
A single molecule of chromosome 2 from malaria that was stretched 
out on glass slides and viewed under the microscope showed that 
the DNA could still be treated with restriction enzymes. So we could 
get restriction digest maps of single molecules of DNA where the 
enzyme cuts the surface tension and the ends pull away, and we can 
just look down the chromosome and see a cut, measure the distance, 
and use this to verify the structure of the genome. This was the first 
malaria chromosome that was published in Science  a few years ago in 
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a program headed by Malcolm Gardner, one of the top parasito-
logists at TIGR. 
 
In fact, Malcolm is heading the team that is studying the East Coast 
fever genome, Theileria parva. East Coast fever is caused by a tick-
borne parasite that causes cattle to die within three or four weeks of 
infection. The parasite enters the blood stream and enters lympho-
cytes and actually transforms them into a cancer-type phenomenon. 
It is the only case where the eukaryotic cell is known to transform 
lymphocytes to create a leukemia-type disease. 
 
This has a tremendous impact in Sub-Saharan Africa, and TIGR was 
asked to help in sequencing the genome; in part to help develop 
new and novel vaccines against this species, even though very few 
parasite genomes were known. 
 
It is a very small eukaryotic genome, in contrast to the pathogens, 
done in collaboration with ILRI. Dr. Gardner has now basically 
completed the sequencing of the genome and is in final closure and 
annotation stages, and will probably publish early next year. 
Already various antigens have been selected for vaccine 
development. 
 
TIGR moved into the plant world and sequenced the first plant 
chromosome from Arabidopsis, a model plant organism, with work 
funded mostly by the U.S. National Science Foundation. And, again, 
there were a lot of surprises, even on the plant chromosomes. The 
gene density was mostly even, except in the region of the centro-
mere, but it had been thought—and the centromere is the hetero-
chromatin of our own chromosomes—that there were no genes. 
TIGR found there are, in fact, a lot of genes in these regions that were 
thought to be to be void of genes, many of them very important 
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essential ones, but about one-tenth the density that were found 
elsewhere. 
 
So TIGR had sequenced genomes, including the tuberculosis genome 
and Deinococcus, that were a high Guanine-Cytosine (GC) content. 
We sequenced over half the chromosomes in Plasmodium, which are 
a very low GC content. And we knew these techniques could be 
applied on a much broader scale to larger species. What was lacking 
was the appropriate technology. 
 
In 1998, Mike Hunkapillar of Applied Biosystems, contacted me 
about a new sequencing instrument he had developed. He thought it 
would be a tool that I needed to actually try to sequence the human 
genome. And, they were willing to consider investing $300 million to 
fund the experiment.  
 
By the end of the first day of looking at this new technology we had 
a plan for sequencing the human genome combining all the tech-
niques we had developed at TIGR for the whole genome shotgun 
sequencing, the new capillary sequencer from Applied Biosystems, 
and a key component for high-end computing that was being 
provided by Compaq. 
 
Following an expansion of the TIGR model, we built a new sequen-
cing factory with 300 of these new $300,000 machines. In contrast to 
roughly 3,000 scientists associated with the public genome effort, it 
took a team of only 50 scientists to sequence the human genome. As 
you can see, we substituted electrons for people. 
 
The facility is a larger version of TIGR. It is a football-field-size room 
full of instruments. But now it only takes nine technicians to run the 
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instruments 24 hours a day, 7 days a week. So automation has 
changed the cost paradigm substantially. 
 
The problem was in analyzing all the data, and we had to build the 
largest civilian supercomputer with the help of Compaq to be able to 
assemble and analyze the human genome. 
 
It was a big leap going from a plant chromosome or the malaria 
chromosome to the human chromosome, and we also knew that 
even if we had the human genome sequence, it would be difficult to 
interpret without other genetic codes. So we chose to test this new 
technology on sequencing the fruit fly genome as a prototypical 
insect. And this is going to have a big impact now as various insect 
species, including the mosquito that carries the malaria parasite and 
others like the tick genome, are analyzed. We now have a basis of an 
insect genome. 
 
This was done in a relatively short period. Once we had the 
sequence, a team of international scientists came to an Annotation 
Jamboree in Rockville, Maryland, and literally camped out for weeks 
while they analyzed the Drosophila genetic code. The Drosophila 
sequence was published in Science  in March 2000, less than a year 
from the start of this project. The next largest genome was the C. 
Elegans genome, which took over eight or ten years to sequence from 
start to finish. So, again, this changed the time and the cost 
paradigm. 
 
When we sequenced the Haemophilus genome, we had to sequence 
26,000 clones, and then it took four months at TIGR. TIGR could 
probably do this in a few weeks now. For Drosophila, we had to 
sequence over three million clones. This was during the scale-up 
period, and it took four months at the time. If we were going to 
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resequence the Drosophila genome, it would take roughly three and a 
half weeks. The Haemophilus genome that took so much time five 
years ago could be done now in two hours, and the yeast genome, 
which was a 12-year project in Europe, could be done in 24 hours. 
 
We are dealing with a fundamental technology change. In terms of 
the computing, five years ago it seemed almost an impossible 
compute for Haemophilus – it took eleven days on a Sun computer to 
assemble the genome. Now, with the new algorithms and the new 
super-computer, it takes less than five minutes to do that same 
calculation. And all this technology is expanding. If anyone had 
asked five years ago whether the Theileria genome would be 
sequenceable in the short period of time that TIGR has done it, we 
would have said it could not be done. So it is a very short history 
with a very dramatic change. 
 
In Drosophila, we found 13,601 genes; roughly only 2,500 of those 
were previously known. A comparison of the first few genomes that 
had been sequenced showed, not surprisingly, a large number of 
unknown genes. We thought once we sequenced a few more we 
would find matches to everything. That, in fact, has not happened. In 
every genome that we, TIGR, or anybody else does, roughly half of 
the genes in that genome are unknown to science. Half again of those 
are highly conserved; in other words, we find that same unknown 
gene in a large number of species. But we still do not have the 
slightest clue what it does. 
 
To get a grant funded in the United States to study biology, a hypo-
thesis is necessary, and without a hypothesis the grant will not be 
funded. The assumption is we know so much about biology that we 
should just be testing hypotheses at this stage. Genomics is clearly 
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saying we are still very much in the descriptive phase of biology and 
will probably be there for most of the rest of this century. 
 
You cannot get a grant to study one of those 103 unknown genes that 
are essential for life in Mycoplasma, and you cannot get a grant to 
study any of the 18,000 genes from the various microbial species, or 
the 60 percent of the fruit fly genome that is completely unknown. So 
it is going to be a real challenge for biology. There are now approxi-
mately over 100,000 new unknown genes, far more genes than in our 
entire human genome, and biology has no idea what role they play. 
This is both a problem and a phenomenal opportunity, because these 
genes are going to represent unique points for intervention and 
therapy, new unique vaccine targets, and unique mechanisms for 
changing the biotechnology revolution. 
 
All we know about the insect world now—and Drosophila is one of 
the most studied species—is about 40 percent of the genome. Most of 
these are new, but at least there are new families in the common 
categories of genes that we know about. In over half the human 
genome, the genes are new to science. 
 
Seymour Benzer's group at Cal Tech characterized a gene that he 
named “Methuselah,” which led to an increased life span in fruit 
flies. When we characterized the fruit fly genome, we found eleven 
Methuselah-like homologues. Everybody who was in that room—
over 50 people—immediately took those to look in the human 
genome to see if we could find new longevity genes, and some of 
those are under investigation. 
 
Gerry Rubin, now the Vice President of Biomedical Research at the 
Howard Hughes Medical Institute, was our key collaborator on the 
Drosophila genome. He characterized all the known human genes 
 
16 
  
 
 
 
and found that over 300 of them had counterparts in the fruit fly 
genome. 
 
Our genes are nearly identical, or many of our proteins are nearly 
identical in structure to those in the fruit fly and other species. But 
now scientists studying these genes and their function in Drosophila 
are moving forward our knowledge of human disease genes that 
affect diseases like cancer. 
 
That is a transition into human. At about the time we announced the 
completion of the Drosophila genome, we switched totally to work on 
the human. We took all the chromosomes together from five people, 
three females and two males, and made individual libraries. On June 
26, 2000, we announced at the White House the successful assembly 
of the 3.12 billion letters of our own genetic code. The public genome 
effort announced at the same time. It was an exciting day for 
everyone. 
 
We have now moved into trying to interpret this information. A lot 
of people in the press and on Wall Street have said, well, now, Celera 
sequenced the genome, genomics is finished, what's the next phase 
of life? Genomics is just getting started. This was a race to the 
starting line. Once there is a genome sequence of the malaria 
genome, research can begin for new treatments and new therapies. 
New malaria vaccines are being tested from the work of Malcolm 
Gardner and Steve Hoffman and their colleagues from the genome 
effort. 
 
Comparative genomics is one of the most important tools going 
forward. Understanding the fruit fly genome will really help us 
understand the human. About eight years ago, we were character-
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izing some of the early ESTs that we did from human, and we 
compared the human sequences to those from E. coli and from yeast. 
Mismatched DNA repair enzymes had been well characterized in 
yeast and E. coli. I do not think anybody would have predicted that 
the genes that cause colon cancer would have been discovered by 
characterizing brewer's yeast and the E. coli that lives in our gut. But 
it was because of the close similarity of genes throughout all species 
that these matches immediately leapt forward. It was very clear 
these human genes, by their close similarities to the counterparts in 
bacteria and yeast, were mismatched DNA repair enzymes. Bert 
Vogelstein's lab at Johns Hopkins, our collaborator on this, quickly 
showed that changes in the genetic code in these genes were the 
cause of non-polyposis colon cancer. 
 
So characterizing a variety of species will have a huge impact. The 
Theileria genome will help us understand things in our own genetic 
code. Understanding the human genome will help interpret the 
Theileria genome. 
 
We have recently announced that we finished sequencing three 
strains of mice to help interpret the human genetic code. If you chop 
up the mouse chromosomes and lay them on top of the human 
chromosomes, they're virtually identical, just some of the order is 
slightly different. 
 
There is a gene called the Pax-6 gene. If this gene is knocked out in 
fruit flies, it leads to what is called an eyeless phenotype. The fruit 
flies have no eyes. If it is mutated or knocked out in mice, it leads to 
blindness. 
 
A disease called aniridia has mutations in the same gene. Children 
are born without an iris. They go blind at an early stage because they 
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cannot regulate the light going into their eyes. It is possible to take 
the human or mouse gene, put it in a fruit fly, and it will rescue the 
phenotype. The parts are conserved through billions of years of 
evolution and are largely interchangeable. 
 
In the sequence of a single human genome there will be about two 
to three million variations. The chromosome set passed down from 
each parent differs from each other in roughly one out of 1,200 
letters. So there are roughly two to three million differences in the 
genetic code from person to person out of over three billion letters. 
 
We have recently announced our database of over 2.8 million of 
these single nucleotide polymorphisms that are being used to 
characterize human disease. They are helping the pharmaceutical 
industry do better clinical trials, find drugs that are more effective, 
and look for hints in the genetic code for detectable toxicity. For 
example, a major Type II diabetes drug was recently taken off the 
market because it caused liver toxicity in one out of 10,000 patients 
taking the drug. If those kinds of toxic events could be predicted in 
advance before the drug is taken, it would fundamentally change 
medicine. It would change the economic condition of one 
pharmaceutical company that lost a billion-dollar-a-year drug, and 
roughly 100 people, I've been told, have died from this severe liver 
toxicity. They would have liked to have known whether that could 
have been predicted in advance. That is the promise that this work 
has. 
 
But as much as people want genetics to be deterministic, it is not, 
with rare exceptions. It is not in the single cell with perhaps 300 
genes. It is not even in the cancer genes I mentioned. If we find these 
mutations in any person, it can tell whether he has a greatly 
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increased risk of getting colon cancer, but it won't tell if he will get 
colon cancer. It won't tell if he won't. 
 
So the next stage is interpreting the genetic code in terms of under-
standing the protein world. The hope is that the genetic code will 
give us predictions. It will tell us who has an increased likelihood, a 
propensity for different diseases. If we can find specific protein 
markers for breast cancer, like the PSA antigen for prostate cancer, 
we think that breast cancer could be detected earlier than by using 
mammography and before a lump would be detected. 
 
If there are 50,000 genes, there may be as many as a million different 
proteins from different combinations. Our complexity comes not 
from the genetic code, but from what happens after that. 
 
We are now building the world's largest protein-sequencing facility 
in Rockville, Maryland, which will allow us to sequence on the order 
of a million proteins a day, comparing things from a large number of 
clinical situations. This is just one of the areas in which genomics is 
essential. Without having the human genome sequence this could 
not be done, because when we sequence proteins with mass spectro-
metry, the proteins get blown apart into small pieces that then get 
compared back to the genetic code for interpretation. 
 
Before we finished the genome, most of the pieces did not match 
anything and the protein structures could not be found. That is now 
changed, and more changes are coming fast. With new technology 
that is being developed by our sister company, Applied Biosystems, 
these machines should be able to do on the order of 10,000 samples 
an hour versus on the order of 100 or so today. 
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We received the first prototype machine just a few weeks ago. This 
is a new "Time of Flight – Time of Flight" mass spectrometry instru-
ment, known as the ”TOF-TOF” for short. It uses two mass spectro-
meters in a row to sequence over 10,000 proteins an hour, and we 
are building out a whole floor to be filled with these machines. 
 
So, whether it's a parasite or whether it's a cancer that grows in our 
own systems, we think this will lead to new approaches, not only for 
diagnosis, but for cancer-specific vaccines by finding the proteins 
that are expressed specifically in different tumors the same way that 
malaria vaccines—and the same way that we hope Theileria vac-
cines—will be developed. We think we have a chance to develop 
new vaccines for diseases such as cancer. 
 
So we are moving from evolving levels of genomic 
information to study the protein world, to a fuller study of 
medicine and the complete spectrum of biology, of which 
agriculture is a very key environmental counterpart. 
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J. Craig Venter, Ph.D. 
 
Celera Genomics 
45 West Gude Drive 
Rockville, MD  20850 
(240) 453-3500 
 
J. Craig Venter, Ph.D. is the President and Chief Scientific Officer of 
Celera Genomics Corporation and the Founder, Chairman of the 
Board and former President of The Institute for Genomic Research 
(TIGR), a not-for-profit genomics research institution. 
 
Between 1984 and the formation of TIGR in 1992, Dr. Venter was a 
Section Chief, and a Lab Chief, in the National Institute of 
Neurological Disorders and Stroke at the National Institutes of 
Health (NIH). In 1990, he developed expressed sequence tags (ESTs), 
a new strategy for gene discovery that has revolutionized the 
biological sciences. Over 72 percent of all accessions in the public 
database GenBank are ESTs from a wide range of species including 
human, plants and microbes. Out of new algorithms developed to 
deal with 100,000’s of sequences TIGR developed the whole genome 
shotgun method that led to TIGR completing the first 3 genomes in 
history and a total of 21 to date. 
 
In May of 1998, Dr. Venter and Perkin-Elmer (now known as 
Applera) announced the formation of Celera Genomics. Celera’s goal 
is to become the definitive source of genomic and medical 
information thereby facilitating a new generation of advances in 
molecular medicine. Celera is building the expertise and information 
that will enable scientists to transform the way in which human and 
health problems are diagnosed and treated. On June 26, 2000, Celera 
announced that it had completed the first assembly of the human 
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genome, which has revealed a total of 3.12 billion base pairs in the 
human genome. On February 16, 2001, Celera’s manuscript on the 
sequencing of the human genome was published in Science 
Magazine.  
 
Dr. Venter has published more than 160 research articles and is one 
of the most cited scientists in biology and medicine. He has been the 
recipient of numerous awards, including the 2000 King Faisal Award 
in Science and was recently selected as a runner up for TIME 
Magazine’s Man of the Year and was selected as Man of the Year for 
the Financial Times. In addition to receiving honorary degrees for his 
pioneering work, he has been elected a Fellow of several societies 
including the American Association for the Advancement of Science 
and the American Academy of Microbiology. He received his Ph.D. 
in Physiology and Pharmacology from the University of California, 
San Diego. 
 
Scientific papers published include: 
· Complementary DNA Sequencing: “Expressed Sequence Tags” and 
the Human Genome Project.  Science 252, 1651-1656 (1991). 
· Potential Virulence Determinants in Terminal Regions of Variola 
Smallpox Virus Genome.  Nature 366, 748-751 (1993).  
· Whole-Genome Random Sequencing and Assembly of Haemophilus 
influenzae Rd. Science  269, 496-512 (1995). 
· Initial Assessment of Human Gene Diversity and Expression 
Patterns Based Upon 52 Million Basepairs of cDNA Sequence.  
Nature 377 suppl., 3-174 (1995). 
· The Minimal Gene Complement of Mycoplasma genitalium .  Science 
270, 397-403 (1995). 
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· Complete Genome Sequence of the Methanogenic Archeon, 
Methanococcus jannaschii.  Science  273, 1058-1073 (1996). 
· The Complete Genome Sequence of the Gastric Pathogen Helicobacter 
pylori.  Nature 388, 539-547 (1997). 
· The Complete Genome Sequence of the Hyperthermophilic, 
Sulphate-Reducing Archaeon Archaeoglobus fulgidus.  Nature 390, 364-
370 (1997). 
· Genome Sequence of the Lyme Disease Spitochaete, Borrelia 
burgdorferi.  Nature 390, 580-586 (1997). 
· Shotgun Sequencing of the Human Genome.  Science 280,  1540-1542 
(1998). 
· Complete Genome Sequence of Treponema pallidum, the Syphilis 
Spirochete. Science 281, 375-388 (1998). 
· Chromosome 2 sequence of the human parasite Plasmodium 
falciparum: Plasticity of a eukaryotic chromosome. Science 282 (5391), 
1126-1132. (1998). 
· Global Transposon Mutagenesis and a Minimal Mycoplasma 
Genome. Science  286, 2165-2169 (1999). 
· Sequence and Analysis of Chromosome 2 of Arabidopsis thaliana. 
Nature 402, 761-767 (1999). 
· Complete Genome Sequencing of the Radioresistant Bacterium, 
Deincoccus radiodurans R1. Science  286, 1571-1577 (1999). 
· The Genome Sequence of Drosophila melanogaster.  Science 287, 2185-
2204 (2000). 
· Sequencing of the Human Genome. Science  291, 1304-1351 (2001). 
 
 
 
 
  
 
 
 
The CGIAR Family.  Created in 1971, the Consultative Group on 
International Agricultural Research (CGIAR) is an association of public and 
private members that support a system of 16 international agricultural 
research centers known as the Future Harvest Centers. The Future Harvest 
Centers work in more than 100 countries to mobilize cutting-edge science to 
reduce hunger and poverty, improve human nutrition and health, and 
protect the environment. The CGIAR's budget in 2000 was US$340 million. 
All new technologies resulting from the Centers' research are freely 
available to everyone. 
 
CGIAR-Supported Future Harvest Centers 
 
· Centro Internacional de Agricultura Tropical (CIAT), www.ciat.cgiar.org 
· Center for International Forestry Research (CIFOR), www.cgiar.org/cifor 
· Centro Internacional de Mejoramiento de Maiz y Trigo (CIMMYT), 
www.cimmyt.cgiar.org 
· Centro Internacional de la Papa (CIP), www.cipotato.org 
· International Center for Agricultural Research in the Dry Areas 
(ICARDA), www.icarda.cgiar.org 
· International Center for Living Aquatic Resources Management 
(ICLARM), www.cgiar.org/iclarm 
· International Centre for Research in Agroforestry (ICRAF), 
www.cgiar.org/icraf 
· International Crops Research Institute for the Semi-Arid Tropics 
(ICRISAT), www.icrisat.org 
· International Food Policy Research Institute (IFPRI), www.cgiar.org/ifpri 
· International Institute of Tropical Agriculture (IITA), www.cgiar.org/iita 
· International Livestock Research Institute (ILRI), www.cgiar.org/ilri 
· International Plant Genetic Resources Institute (IPGRI), 
www.ipgri.cgiar.org 
· International Rice Research Institute (IRRI), www.cgiar.org/irri 
· International Service for National Agricultural Research (ISNAR), 
www.cgiar.org/isnar 
· International Water Management Institute (IWMI), www.cgiar.org/iwmi  
· West Africa Rice Development Association (WARDA), 
www.cgiar.org/warda 
 
CGIAR members.  The CGIAR partnership includes 22 developing and 21 
industrialized countries (South Africa has been a member since 1997), 3 
private foundations, and 12 regional and international organizations. The 
Food and Agriculture Organization of the United Nations (FAO), United 
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Nations Development Programme (UNDP), and the World Bank serve as 
cosponsors. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The CGIAR Secretariat 
The World Bank 
1818 H Street, NW, MSN G6-601 
Washington, DC 20433, USA 
Tel: (1-202) 473-8951 Fax: (1-202) 473-8110 
E-mail: cgiar@cgiar.org or cgiar@worldbank.org 
www.cgiar.org 
 
